Black Diamond Therapeutics, Inc. BDTX

About Black Diamond Therapeutics, Inc. (BDTX): stock profile, AI score and financials

Black Diamond Therapeutics, Inc. (BDTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDTX at 37.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,228 of 3,064 stocks — the bottom half of the AI-ranked universe. BDTX scores in the top quartile across balance sheet strength (100.0). Areas of concern include institutional flow (15.7) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.3/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of BDTX by reported 13-F value include NEA Management Company, T. Rowe Price Investment Management, BlackRock, based on the most recent SEC filings. BDTX trades on the Nasdaq exchange and files with the SEC under CIK 1701541. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Black Diamond Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1701541 →